Bulaquine

Bulaquine (CDRI 80/53) is a potent antimalarial agent which is an analogue of Primaquine. Bulaquine affects multiple metabolism pathways and shows inhibition effect on Plasmodium cynomolgi infection. Bulaquine can be used for the research of malaria[1][2][3].

Product Specifications

CAS Number

79781-00-3

Product Name Alternative

CDRI 80/53; Elubaquine

UNSPSC

12352005

Target

Parasite

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/bulaquine.html

Solubility

10 mM in DMSO

Smiles

C/C(NCCCC(NC1=CC(OC)=CC2=C1N=CC=C2)C)=C3C(OCC/3)=O

Molecular Formula

C21H27N3O3

Molecular Weight

369.46

References & Citations

[1]Noel S, et al. Identification of differentially expressed genes after acute exposure to bulaquine (CDRI 80/53) in mice liver. Basic Clin Pharmacol Toxicol. 2008 Dec;103 (6) :522-9.|[2]Dutta GP, et al. Radical curative activity of a new 8-aminoquinoline derivative (CDRI 80/53) against Plasmodium cynomolgi B in monkeys. Am J Trop Med Hyg. 1989 Dec;41 (6) :635-7.|[3]Wells TN, et al. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol. 2010 Mar;26 (3) :145-51.Wells TN, et al. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol. 2010 Mar;26 (3) :145-51.